Find FDA Investigational New Drug (IND) Submissions for Infections and Infectious Diseases

Lead Product(s): ALS-4

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2020

Details:

Subject to completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in second half of 2020 and commence a phase 1 trial in North America.

Lead Product(s): NV-HHV-101

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

NV-HHV-101 was found to be safe in terms of potential genotoxicity in the suite of tests that were performed by an independent laboratory.

Lead Product(s): NV-HHV-101

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $2.2 million Upfront Cash: $2.2 million

Deal Type: Funding January 06, 2020

Details:

The current cash infusion provides an effective runway anticipated to enable the company to file its first IND application and further continuing operations.